For how we live.
The first double-blind sham-controlled trial of pulmonary vein isolation found quality of life improved in both arms. Most of the benefit patients feel appears not to come from the ablation.
THESUS-HF II enrolled 1,578 patients across 50 hospitals in 17 countries. Guideline drugs were prescribed at discharge in most patients, and target doses were reached in fewer than half.
A secondary analysis of the VITAL-AF trial reports a screening benefit only in the top risk decile — with a confidence interval whose lower bound sits at 0.01.
Among 1.2 million participants in Paris endurance races over ten years, 17 suffered sudden cardiac arrest. Nearly all of them lived, and researchers still can't explain almost half the cases.
The clearance is the third in a growing family of machine-learning notification algorithms built to spot serious cardiac conditions from a routine 12-lead ECG, a test most patients already get.
The STABLED trial randomized 331 atrial fibrillation patients with a recent stroke to ablation plus anticoagulation or anticoagulation alone. The two groups ended up nearly identical.
An individual-patient meta-analysis of 17,801 patients found a hazard ratio of 0.97 for death, reinfarction or heart failure — a result precise enough to make the question look settled.
EchoNext scored 77.3% accuracy on a 150-ECG set where 13 cardiologists averaged 64.0%. Its authors released the model weights and a 100,000-ECG labelled dataset alongside the paper.